ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 2369

Investigating Macrophage Heterogeneity in the Esophagus of SSc Patients
Abstract Number: 0063

Investigating Macrophage Repopulation in the Synovium
Abstract Number: 0723

Investigating the Effects and Molecular Mechanisms of TRAF5 on the Pathogenesis of SLE Associated Pulmonary Arterial Hypertension
Abstract Number: 1208

Investigating the Experiences of Patients Living with Antiphospholipid Antibodies: A Qualitative Study
Abstract Number: 1826

Investigating the Health Profiles and the Prevalence and Correlates of Cannabis Use Among Patients Accessing Rheumatologic Care in Alberta, Canada
Abstract Number: 0675

Investigating the Impact of anti-IL5 Therapy in the Management of Relapsing and Refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA); A Three Year Longitudinal Perspective and Beyond
Abstract Number: 0919

Investigating the Role of Interferon in Promoting Flares of SLE at a Single Cell Level
Abstract Number: 0893

Involvement of Type I Interferon-responsive Myeloid Cells in Renal Inflammation in a Lupus Mouse Model
Abstract Number: 2031

Involving Patients Research Partners in Research in Rheumatology: Where Do We Stand? A Scoping Review of Recent Randomized Controlled Trials and Translational Science Studies
Abstract Number: 2242

Irrespective of the Number of Erosions at Baseline, Patients with Psoriatic Arthritis Treated with Ixekizumab Show Improved Clinical Outcomes
Abstract Number: 0604

Is Belimumab Dose Optimization Possible in Patients with Systemic Lupus Erythematosus?: Analysis of This Therapeutic Strategy in a Large Multicenter Cohort of Patients from Spanish Rheumatology Departments
Abstract Number: 1865

Is Flexion Contracture in Knee Osteoarthritis Associated with MRI Pathologies over Time? Data from the Osteoarthritis Initiative
Abstract Number: 2292

Is Machine Learning Useful to Predict Flare During Pregnancy in Systemic Lupus Erythematosus?
Abstract Number: 2354

Is Midkine a Novel Biomarker for Acro-osteolysis in Systemic Sclerosis?
Abstract Number: 2368

Is Skin Disease a Local Manifestation of Systemic Tissue Turnover? Serological Collagen Biomarkers Provide Important Information on Skin Diseases Arising from Mutations in Collagen Genes

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].